Cytokine release by murine spleen cells following multiple low dose streptozotocin-induced diabetes and treatment with a TNFα transcriptional inhibitor

International Immunopharmacology

Volumn 3, Issue 12, 2003, Pages 1609-1617

  Thorvaldson, Lina ^a   Holstad, Maria ^a   Sandler, Stellan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cytokine; Mice; Streptozotocin; TNF ; Type 1 diabetes

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; MDL 201449A; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG INHIBITION; EXPERIMENTAL MODEL; IN VIVO STUDY; INTERFERON PRODUCTION; LOW DRUG DOSE; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REBOUND; SPLEEN CELL; STREPTOZOCIN DIABETES; TH1 CELL;

EID: 0141526320     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00183-8     Document Type: Article

References (28)

1. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 14:1998;129-151.
2. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
3. Kolb H. Benign versus destructive insulitis. Diabetes Metab. Rev. 13:1997;139-146.
4. Pakala S.V., Chivetta M., Kelly C.B., Katz J.D. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J. Exp. Med. 189:1999;1053-1062.
5. Ogawa J., Takahashi S., Fujiwara T., Fukushige J., Hosokawa T.et al. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci. 65:1999;1287-1296.
6. Beales P.E., Liddi R., Giorgini A.E., Signore A., Procaccini E.et al. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. Eur. J. Pharmacol. 357:1998;221-225.
7. Rothe H., Fehsel K., Kolb H. Tumour necrosis factor alpha production is upregulated in diabetes prone BB rats. Diabetologia. 33:1990;573-575.
8. Leiter E.H. Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: influence of inbred background, sex, and thymus. Proc. Natl. Acad. Sci. U. S. A. 79:1982;630-634.
9. Like A.A., Rossini A.A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 193:1976;415-417.
10. Kolb-Bachofen V., Epstein S., Kiesel U., Kolb H. Low-dose streptozocin-induced diabetes in mice. Electron microscopy reveals single-cell insulitis before diabetes onset. Diabetes. 37:1988;21-27.
11. Herold K.C., Vezys V., Sun Q., Viktora D., Seung E.et al. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J. Immunol. 156:1996;3521-3527.
12. Holstad M., Sandler S. A transcriptional inhibitor of TNF-α prevents diabetes induced by multiple low-dose streptozotocin injections in mice. J. Autoimmun. 16:2001;441-447.
13. Edwards C.K. III, Zhou T., Zhang J., Baker T.J., De M.et al. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-α J. Immunol. 157:1996;1758-1772.
14. Bradshaw M., Rutherford M.S., Hoeper B.J., McWhinney C.D., Borcherding D.R.et al. Specific transcriptional inhibition of bone marrow-derived macrophage tumor necrosis factor-α gene expression and protein production using novel enantiomeric carbocyclic nucleoside analogues. J. Pharmacol. Exp. Ther. 273:1995;1506-1518.
15. Li Z., Karlsson F.A., Sandler S. Islet loss and alpha cell expansion in type 1 diabetes induced by multiple low-dose streptozotocin administration in mice. J. Endocrinol. 165:2000;93-99.
16. Sandler S. Protection by dimethyl urea against hyperglycaemia, but not insulitis, in low-dose streptozotocin-induced diabetes in the mouse. Diabetologia. 26:1984;386-388.
17. Muller A., Schott-Ohly P., Dohle C., Gleichmann H. Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin. Immunobiology. 205:2002;35-50.
18. Nicoletti F., Di Marco R., Conget I., Gomis R., Edwards C. IIIet al. Sodium fusidate ameliorates the course of diabetes induced in mice by multiple low doses of streptozotocin. J. Autoimmun. 15:2000;395-405.
19. Schloot N.C., Hanifi-Moghaddam P., Goebel C., Shatavi S.V., Flohe S.et al. Serum IFNγ and IL-10 levels are associated with disease progression in non-obese diabetic mice. Diabetes Metab. Res. Rev. 18:2002;64-70.
20. Itoh M., Funauchi M., Sato K., Kisamori S., Fukuma N.et al. Abnormal lymphocyte function precedes hyperglycaemia in mice treated with multiple low doses of streptozotocin. Diabetologia. 27:1984;109-112. [Suppl.].
21. Kallan A.A., Duinkerken G., de Jong R., van den Elsen P., Hutton J.C.et al. Th1-like cytokine production profile and individual specific alterations in TCRBV-gene usage of T cells from newly diagnosed type 1 diabetes patients after stimulation with beta-cell antigens. J. Autoimmun. 10:1997;589-598.
22. Szelachowska M., Kretowski A., Kinalska I. Decreased in vitro IL-4 and IL-10 production by peripheral blood in first degree relatives at high risk of diabetes type-I. Horm. Metab. Res. 30:1998;526-530.
23. Shanmugam N., Reddy M.A., Guha M., Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes. 52:2003;1256-1264.
24. Schiekofer S., Andrassy M., Chen J., Rudofsky G., Schneider J.et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor κB in PBMCs. Diabetes. 52:2003;621-633.
25. Weiss R.B. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat. Rep. 66:1982;427-438.
26. Karunanayake E.H., Baker J.R., Christian R.A., Hearse D.J., Mellows G. Autoradiographic study of the distribution and cellular uptake of (14C)-streptozotocin in the rat. Diabetologia. 12:1976;123-128.
27. Nichols W.K., Vann L.L., Spellman J.B. Streptozotocin effects on T lymphocytes and bone marrow cells. Clin. Exp. Immunol. 46:1981;627-632.
28. Wellhausen S.R. Definition of streptozocin toxicity for primary lymphoidal tissues. Diabetes. 35:1986;1404-1411.